Granted Patent B2

US 12,420,113 · App. 18/194,513 · Granted Sep 23, 2025

Inventors: Michael D. Story (Dallas, TX); Debabrata Saha (Carrollton, TX); Narasimha Kumar Karanam (Dallas, TX)

Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

A61N5/1031A61K31/4725A61N5/1039A61P35/00

Abstract

Claims (36)

1. A method of treating a tumor in a subject, comprising:

applying a tumor treating field to the tumor at a frequency between 50 kHz and approximately 1,000 kHz; and

delivering personalized ultra-fractionated adaptive radiotherapy to the subject comprising:

administering a first pulse dose of radiation to the tumor within the subject,

administering a second pulse dose of radiation to the tumor, wherein the second pulse dose is administered after an observation period, the observation period having a duration of at least 7 days, and

concurrently treating the subject with an immunotherapy.

2. The method of claim 1 , wherein the tumor treating field establishes a conditional vulnerability with the tumor.

3. The method of claim 1 , wherein the first and second pulse doses of radiation are ablative.

4. The method of claim 3 further comprising, in response to administering the first pulse dose, determining at least one of a level of radiation for the second pulse dose, the duration of the observation period, and a target field for the second pulse dose.

5. The method of claim 4 , wherein the first pulse dose of radiation is 8 Gy.

6. The method of claim 4 further comprising, analyzing radiomic features and biologic features.

7. The method of claim 6 , wherein the biologic features comprise at least one of target tissue vascularity, normal tissue vascularity, target tissue oxygenation status, normal tissue oxygenation status, target tissue cytokine profile, normal tissue cytokine profile, target tissue gene expression, normal tissue gene expression, circulating tumor DNA indicative of tumor response to therapy, the levels of circulating tumor cells, target tissue receptor expression, normal tissue receptor expression, target tissue white blood cell infiltration, normal tissue white blood cell infiltration, tumor markers, tumor burden, systemic immune status, changes in subject health, and changes in patient weight.

8. The method of claim 6 , wherein the radiomic features comprise at least one anatomical imaging characteristics, functional imaging characteristics, and metabolic imaging characteristics.

9. The method of claim 1 , wherein an intensity of the tumor treating field is between approximately 1 V/cm and approximately 4 V/cm.

10. The method of claim 1 , wherein the frequency of an alternating electric field is between 80 and 300 kHz.

11. The method of claim 1 , wherein the tumor treating field is applied for 7 continuous days.

12. The method of claim 4 , wherein the second pulse dose is between 15 Gy and 50 Gy.

13. The method of claim 1 , further comprising delivering a DNA replication stress inducing agent to the tumor.

14. The method of claim 13 , wherein the DNA replication stress inducing agent comprises at least one of a platinum compound, an alkylating agent, a wee1 inhibitor, a Chk1 inhibitor, a thymidylate synthase inhibitor, a ribonucleotide reductase inhibitor, Topoisomerase I inhibitor, Topoisomerase II inhibitor, a maternal embryonic leucine zipper kinase (MELK) inhibitor, or a NEDD8-activating enzyme (NAE) inhibitor.

15. The method of claim 14 , wherein the DNA replication stress inducing agent is delivered to the tumor comprising a platinum compound, the platinum compound further comprising at least one of cisplatin, carboplatin, oxaliplatin, dicycoplatin, or lipoplatin,

wherein if the DNA replication stress inducing agent delivered to the tumor is the alkylating agent, the alkylating agent comprises at least one of cyclophosphamide or temozolomide,

wherein if the DNA replication stress inducing agent delivered to the tumor is the wee1 inhibitor, the wee1 inhibitor comprises at least one of Adavosertib-MK1775 or PD0166285,

wherein if the DNA replication stress inducing agent delivered to the tumor is the Chk1 inhibitor, the Chk1 inhibitor comprises at least one of UCN-01, LY2606368, SAR-020106, AZD7762, or PD0166285,

wherein if the DNA replication stress inducing agent delivered to the tumor is the thymidylate synthase inhibitor, the thymidylate synthase inhibitor comprises at least one of 5-FU or pemetrexed,

wherein if the DNA replication stress inducing agent delivered to the tumor is the ribonucleotide reductase inhibitor, the ribonucleotide reductase inhibitor comprises gemcitabine,

wherein if the DNA replication stress inducing agent delivered to the tumor is the Topoisomerase I inhibitor, the Topoisomerase I inhibitor comprises at least one of Irinotecan or Topotecan,

wherein if the DNA replication stress inducing agent delivered to the tumor is the Topoisomerase II inhibitor, the Topoisomerase II inhibitor comprises at least one of etoposide or doxorubicin,

wherein if the DNA replication stress inducing agent delivered to the tumor is the MELK inhibitor, the MELK inhibitor comprises OTS167, and

wherein if the DNA replication stress inducing agent delivered to the tumor is the NAE inhibitor, the NAE inhibitor comprises MLN4924.

16. The method of claim 13 , further comprising delivering an additional DNA replication stress inducing agent to the tumor.

17. The method of claim 1 , further comprising delivering at least one of an E2F inhibitor, a CDK4/6 inhibitor, or a PARP inhibitor.

18. The method of claim 17 , wherein the E2F inhibitor is delivered to the tumor, and wherein the E2F inhibitor is HLM006474.

19. A method of treating a tumor in a subject, comprising:

applying a tumor treating field to the tumor at a frequency between 50 kHz and approximately 1,000 kHz;

delivering personalized ultra-fractionated adaptive radiotherapy to the subject; and

delivering a DNA replication stress inducing agent to the tumor.

Assignments (2)

Continuity (2)

References Cited (149)